Takeda Pharmaceutical Co Ltd TAK
Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a GI/hepatology drug developer. Its lead program, ENTYVIO (vedolizumab), is in Phase 3 for Ulcerative colitis and Crohn's disease (IBD). Its next catalyst on record is zasocitinib (TAK-279): FDA PDUFA target action date (NDA under Priority Review) (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: zasocitinib (TAK-279) — FDA PDUFA target action date (NDA under Priority Review) (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ENTYVIO (vedolizumab) | UC, Crohn's disease; pediatric sBLA under FDA review | antibody | Approved |
| ADZYNMA (recombinant ADAMTS13) | congenital TTP | protein/peptide | Approved |
| VYVANSE (lisdexamfetamine) | ADHD | small molecule | Approved |
| zasocitinib (TAK-279) | moderate-to-severe plaque psoriasis | small molecule | Phase 3 |
| oveporexton (TAK-861) | narcolepsy type 1 | unclear | Phase 3 |
| fazirsiran (TAK-999) | alpha-1 antitrypsin deficiency-associated liver disease | RNA (siRNA/ASO/mRNA) | Phase 3 |
| mezagitamab (TAK-079) | IgA nephropathy; immune thrombocytopenia | antibody | Phase 1 |
Recent results and decisions
- Oct 1, 2026positive VERDICT trial showed ENTYVIO reduced UC complication risk by nearly 70 percent with disease clearance target.
treating adults with intravenous ENTYVIO to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication, reducing UC complication risk by nearly 70 percent.
Filing - Oct 1, 2026met Phase 3 G-HOPE-001 study met both primary endpoints of OS and PFS with arcotatug tavatecan.
The G-HOPE-001 study met both prespecified primary endpoints of overall survival (OS) and progression-free survival (PFS), with arcotatug tavatecan demonstrating statistically significant improvements compared with treatment of physician's choice.
Filing - positive VERDICT trial showed ENTYVIO IV treating to disease clearance reduced UC complication risk by nearly 70 percent versus symptomatic remission alone.
In October 2026, Takeda announced new data from the VERDICT trial, showing that treating adults with intravenous ENTYVIO to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related com
Filing
29 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 GI/hepatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.